China Jo-Jo Drugstores Inc CJJD

Healthcare

China Jo-Jo Drugstores Inc, formerly China Jo-Jo Drugstores Holdings Inc, is a China-based retailer and distributor of pharmaceutical and other healthcare products. The Company operates in four business segments. The Retail Drugstores segment sells prescription and over the counter (OTC) medicines, traditional Chinese medicine (TCM), dietary supplements, medical devices, and sundry items to retail customers. The Online Pharmacy segment sells OTC drugs, dietary supplements, medical devices and sundry items through its own and third-party platforms. The Wholesale Business segment includes supplying the Company's own retail drugstores and selling them to other drug vendors and hospitals. The Farming and Selling Herbs segment cultivates selected herbs for sales to other drug vendors.

NDAQ:CJJD - Post by User

China Jo-Jo Drugstores Inc

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Apr 19, 2023 10:47am

92 Views

Post# 35402923

CJJD....... Take a look

Fiscal Year 2022 Financial Highlights

	For the Year Ended March 31,
($ millions, except per share data)	2022	2021	% Change
Revenue	164.39	133.13	23.5 %
Retail drugstores	84.23	76.10	10.7 %
Online pharmacy	30.22	22.48	34.4 %
Wholesale	49.94	34.55	44.6 %
Gross profit	36.52	29.24	24.9 %
Gross margin	22.2 %	22.0 %	0.2 pp*
Loss from operations	(2.69)	(8.84)	69.5 %
Net loss	(3.20)	(8.38)	61.8 %
Loss per share	(0.92)	(2.39)	61.5 %

*Notes: pp represents percentage points

Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year.
Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year.
Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year.
Net loss was $3.20 million, or $0.92 per basic and diluted share, for the fiscal year ended March 31, 2022, compared to net loss of $8.38 million, or $2.39 per basic and diluted share, for the same period of last year.